Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK1120212 plus Gemcitabine in Metastatic Pancreatic Cancer
NCT01231581Phase 2Completed
- Sponsor
- GSK
- Start
- Aug 2010
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing GSK1120212 + Gemcitabine with Placebo + Gemcitabine (2 arms). Primary endpoint: Overall Survival up to 24 months. Started Aug 2010; status: completed.
02
Drugs
trametinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01231581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01231581.